Condition: Pancreatic Adenocarcinoma · Sponsor: Hamilton Health Sciences Corporation
This is a single-arm, single-center feasibility trial of patients with borderline resectable pancreatic adenocarcinoma receiving chemotherapy with mFOLFIRINOX or gemcitabine / nab-paclitaxel followed by pancreatectomy.
This description comes directly from the study's public registry record.
Leyo Ruo, MD · 905-521-2100 · ruol@mcmaster.ca
Pablo E Serrano, MD · 905-521-2100 · serrano@mcmaster.ca
Always discuss trial participation with your own doctor first.
| Juravinski Hospital | Hamilton, Ontario, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04452461